Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Adolor Corporation
Exton, Pennsylvania, United Statesadolor.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Adolor’s lead product was ENTEREG® (alvimopan), an FDA-approved mu-opioid receptor antagonist for accelerating gastrointestinal recovery post-bowel resection. The company also developed ADL5945/OpRA III for OIC/OBD in Phase 2 trials. Additional pipeline included delta opioid receptor agonists with Pfizer for chronic pain.
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small molecules (opioid receptor antagonists and agonists)
- Industry
- Biotech
02
Partnerships
GlaxoSmithKline (co-promotion/commercialization partner for ENTEREG until mid–2011)Pfizer Inc. (collaboration on delta opioid agonists)Eli Lilly & Co. (licensor of OpRA III/ADL5945)
Beyond the preview
Go deeper on Adolor Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adolor Corporation.